Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.
0/5 보강
APA
Schneider J, Hill J, et al. (2026). Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.. Journal of the American Academy of Dermatology, 94(3), 1017-1019. https://doi.org/10.1016/j.jaad.2025.11.057
MLA
Schneider J, et al.. "Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.." Journal of the American Academy of Dermatology, vol. 94, no. 3, 2026, pp. 1017-1019.
PMID
41276126 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24).
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.